Linagliptin, classified as a potent DPP4 inhibitor [98], may mitigate cerebral vascular pathology associated with T2D and other diseases related to abnormal vascular formation, potentially slowing or inhibiting brain disorder progression [99]. The gene discussed is DPP4; the disease is brain disorder.